Adverse Events or Product Complaints
To report suspected adverse events or product complaints in the United States, please call 1-877-411-2510 (option #1) or email [email protected] (option #2). You may also report suspected adverse events to the Food and Drug Administration (FDA) directly at 1-800-FDA-1088 or www.fda.gov/MedWatch.
Covis Pharma is committed to supporting researchers and healthcare providers expand clinical knowledge and understanding through research and education.
Covis supports educational activities in our therapeutic areas of expertise to maintain, develop or increase knowledge, skills and professional performance of healthcare providers. To request review of your educational grant, please complete and submit the Educational Grant Application (link below). Please include a summary of your request on your institutional letterhead accompanied by an IRS W9 form (US Only), Proof of Accreditation (ACCME, ACPE, or other) via certificate, detailed budget, and tentative agenda. Your application must be received at least 60 days prior to the event in order to be considered. We will then contact you to inform you of our decision. If you have further questions, please contact [email protected].
Investigator-Sponsored Research (ISR)
Covis considers requests for support of Investigator-Sponsored Research (ISR) involving our marketed products and/or in our therapeutic areas of expertise. Covis can decide to provide support in funding and/or the provision of drug. Covis receives requests for ISR support regularly and will evaluate proposals based on their scientific merit, clinical relevance and unmet medical needs.
To request review/consideration of your ISR, please review Covis’ ISR Areas of Interest, complete and submit the ISR Concept Form, and provide a budget summary and the Principal Investigators’ CV (link below). The ISR Review Committee meets monthly and reviews all applications. Following submission of your application, a thorough review will occur generally within 30 days. We will then contact you to render our decision. If you have further questions, please contact [email protected].